News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TRANSGENE (ENX:TNG) Reports Progress With Its Proprietary Oncolytic Immunotherapy To Treat Solid Tumors


5/15/2014 12:06:49 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG), a French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases, today provided an update on TG6002, Transgene’s proprietary oncolytic immunotherapy being developed for the treatment of solid tumors. TG6002 was discovered and designed by Transgene, which owns all development and commercialization rights to the program. TG6002 is currently in pre-clinical testing and has shown activity in several human tumor mouse models. The Company currently plans to initiate human clinical testing in 2015.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES